Pfizer (PFE) CEO Isn’t Ready For A Fight With RFK Jr., Says Jim Cramer

We recently published 10 Stocks Jim Cramer Talked About.  Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked about.

Pharma giant Pfizer Inc. (NYSE:PFE)’s shares are down by 4.7% over the past year and flat year-to-date. UBS initiated coverage of the stock in January as it set a Neutral rating for the shares and a $25 share price target. UBS explained that between $15 billion to $20 billion in Pfizer Inc. (NYSE:PFE)’s revenue is tied to drugs that will lose patent protection over the next three years. The commentary followed BMO’s note in December, which had kept an Outperform rating and a $30 share price target on Pfizer Inc. (NYSE:PFE)’s shares. BMO pointed towards the pharma company’s coronavirus business as it outlined that its sales could dip by 23% annually to $5 billion. Pfizer Inc. (NYSE:PFE) appears to be focusing on its drug pipeline as the firm reported positive data for its PADCEV (enfortumab vedotin) drug for bladder cancer when combined with Merck’s blockbuster drug Keytruda. However, instead of Pfizer Inc. (NYSE:PFE)’s pipeline, Cramer discussed the firm in the context of Health Secretary RFK Jr.:

“Pfizer, you know, principal vaccine company in the country. I think we have to accept Carl that the vaccine business is under fire. I don’t think that Dr. Bourla is ready for a fight with RFK Jr. I think RFK Jr. wins on this. Let’s see what Pfizer has to say, cause they actually have a lot of important vaccines that maybe should be called into question.”

Time to Go Short on Pfizer (PFE)?

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.